Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We'll see if this is enough to keep you and Danish out.
https://amp.cnn.com/cnn/2024/03/21/tech/social-media-pump-dump-discord-twitter
It's apparent you and some others here will take poor retail down with the ship, blaming shorts instead of management and yourselves.
What part of "In the fall" don't you understand?
>>shorts continue their work… and then they amplify the dilution that THEY caused.
Nemesis, nobody here will help me verify this. Where'd you find that information please?
>>I was referring to the NWBO Shares, Kings Health Partnership holds.
$50,000...That's a Big Biz Show charge for NWBO.
>>WASHINGTON, Ill. (WMBD) — Every third Wednesday of July is hailed as National Glioblastoma Awareness Day.
Almost 15,000 people in America are given the fatal diagnosis of glioblastoma every year. It’s a brain tumor that is virtually untreatable, with research that has barely improved over the hundred years since it was first identified.
“As we learned more and more and again over the last five years, something that does not sit well with me, is there’s really been no progress in the standard of care for over 25 years,” Jodi Brown, a KBStrong board member, said.
https://www.centralillinoisproud.com/news/local-news/glioblastoma-awareness-day-the-organization-making-a-difference/amp/
Disciples here better get on the phone with Brendon. Eye rolls.
https://www.wcia.com/news/health-news/cancer-center-at-illinois-raises-glioblastoma-awareness/amp/
It'd be a pretty big waste to run this Plll trial if L was about to be the new SOC.
https://www.clinicaltrialsarena.com/news/ivy-brain-tumor-center-glioblastoma-trial/
On YT. "Elvis Presley - Thank You Very Much"
LearningCurve always getting it more right than wrong.
The ASM is a hedge fund festival.
It's what they refuse to answer.
Anyone is this true? Because if it is it somehow got by me.
>>I was referring to the NWBO Shares, Kings Health Partnership holds.
Always the shill excuse.
The day Nemesis showed up with his serious claims I told you all to immediately make management aware to let them respond. Here we are months later and nothing but the usual pumpers arguing with him.
Spoofers on the toilet.
For a moment there I thought you were talking about this Mr. White. Sigh.
https://www.prnewswire.com/news-releases/ronin-trading-and-sw-investment-management-release-presentation-highlighting-concerns-with-board-of-peregrine-pharmaceuticals-300545548.html
Unfortunately nobody appears to be coming to the rescue. No Ronin-PPHM like activity or any sign of interceding. Just Bigger complaining on social media while every other heavy hitter appears to have run for the hills while leaving retail holding the bag again.
Shorts on beach in shorts shorting with some without shorts naked and shortly spoofing. 24/7 for ten years!
Is it next Friday yet?
That's the problem with am radios.
>>Statical Significant 2 words
Simply show it, that's all I ask.
>>You are wrong that it is not in writing, it is. Without it, they could not have submitted for approval.
Elaborate please. The trial started years before Advent was even an idea. It'd be brilliant if the FDA allowed it. Cost are higher in the UK than in the U.S. so maybe not so brilliant.
>>The trial was also run in the UK. They did not switch to the UK, they simply selected the UK, because they thought their chance for approval was greater and Advent can import the tumor tissue to the UK from the US and export the Vaccine. It’s brilliant!
LOL...LP's dream shareholder.
"I’m used to the share price tumbling… it really means little to me."
Funds just transferring from one dinosaur to another.
It really does bring up the question; Is NWBO, DCVAX, and its crew dinosaurs or not? I'm on the fence. Most of it really does feel old.
Who are you speaking of please?
>>My only comfort is that any multi-million share packages received for services tendered,
Never trust an article without a date. It's meant for max pumping.
This is not a good line to use around shareholders here.
>>like sand through the hourglass these are the days of our lives
Gary's back!!!
I only care what the company puts in its filings. If MHRA approved the SAP with the changed endpoint they should say so by updating that paragraph I posted.
You completely ignored the article I posted here where Mulholland said there's been no real change in GBM outcomes in twenty years, and was providing patients a promising new therapy that was not DCVAX-L.
MHRA SAP approval is not in writing anywhere, bottom line. A disciple here discovered something alluding to it on a site. Management seems to almost have wished nobody had.
>>which is why the clinical trials site changed in Europe to reflect their SAP approva
Everyone's concern not just mine!
>>Your concern not mine.
Show us where it says that in a filing.
>>MHRA approved the SAP ahead of time so your concern only applies to FDA review at best
BS! Time is money.
No. It's a specific warning about the single Plll and its difficulties.
>>On October 5, 2020, the Company announced that Data Lock for the Phase III trial had been reached, and that a series of steps and processes would follow. These processes included data validation, analyses of the data by independent statisticians, preparations by the statisticians of summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, in preparation for publication in a scientific journal and public announcement. This series of processes is under way. It is anticipated that public announcement will follow these processes.
Both of these endpoints were confounded: the PFS endpoint by pseudo-progression, and the OS endpoint by the “crossover” provision in the trial design, which allowed all of the patients in the trial to cross over to DCVax-L treatment after tumor recurrence (while remaining blinded as to which treatment they received before tumor recurrence). The statistical analysis plan uses external control patients rather than within-study controls. There can be no assurance that regulatory authorities will allow a product approval to be based upon this approach.
They mean generational wealth for management.
Like I keep saying, Advent is just a bunch of skilled tech and execs renting the Sawston facility and equipment, so it's not quite the same as Cognate. I'm curious to see how it all unfolds. LP could sell Advent claiming she wants to distance herself. But I still think Huawei and partners would make the most sense and bring in the most $$ for LP, if the UK government allows it.
Poor Doc, very confused. Caught again. LOL.
Aka Running out the clock.
>>while we've grown to expect everything to take longer than reasonable.
More BS from you. Show me the "approved" and "accepted" language please.
>>Typically, companies conduct multiple late-stage clinical trials of their product candidates before seeking product approval. Our current Phase III 331-patient clinical trial of DCVax-L for GBM is our first late-stage trial. We may be required to conduct additional late-stage trials with DCVax-L for GBM before we can obtain product approval. This would substantially delay our commercialization, and might not be possible to carry out, due to development and/or approval of competing products, lack of funding, and/or other factors. In addition, our Phase III trial of DCVax-L was placed on a partial clinical hold for new screening for enrollment in 2015. Although the FDA lifted its hold in February 2017 as previously reported by the Company, the Company had already closed enrollment with 331 of the planned 348 patients. Since we did not enroll the last 17 of the planned 348 patients, this could adversely affect the statistical and other analyses of our Phase III trial results and could make it more difficult to seek product approval or more likely that further trials could be required. I
There can be no assurance that regulatory authorities will allow a product approval to be based upon this approach.
But I thought you are a "Fudster"??